Back to Search
Start Over
Efficacy of the BEACOPP regimen in refractory and relapsed Hodgkin lymphoma.
- Source :
-
Leukemia & lymphoma [Leuk Lymphoma] 2009 Nov; Vol. 50 (11), pp. 1803-8. - Publication Year :
- 2009
-
Abstract
- The BEACOPP regimen is a consolidated first-line treatment regimen for advanced stage Hodgkin lymphoma (HL), while few data are available on the efficacy of this regimen in advanced disease. About 50% of patients with HL relapsed after or refractory to first-line therapy achieve a durable response after peripheral blood stem cell transplantation (PBSCT). Patients relapsing after a PBSCT (performed as second line therapy) have a very poor prognosis. We evaluated the efficacy of BEACOPP in two settings: patients refractory or in relapse after first-line therapy (Group A) and patients relapsing after a PBSCT (Group B). Twenty-three patients with HL, admitted between February 2003 and April 2007, were retrospectively studied: 10 patients in Group A and 13 in Group B. Group A: Nine complete remissions (CR) and one partial remission (PR) were achieved following BEACOPP treatment. After a median follow-up of 32 months, one patient has died due to secondary leukemia, while the other eight are alive, five (50%) in second CR, three in third CR after PBSCT and one with disease. Group B: Eight of the 13 patients (62%) obtained a CR, one patient a PR, two were refractory and two have died of toxicity. To date, eight patients (62%) are alive, four (31%) still in CR. All patients experienced hematologic toxicity (WHO 3-4) with two deaths due to septic shock. These results show that BEACOPP is an effective regimen for both refractory/relapsed patients with HL after first-line treatment (Group A) and for patients relapsing after a PBSCT (Group B) with a 3-year probability of overall survival, progression-free survival, and cumulative incidence of relapse of 90, 50, and 33.3% in Group A, and 61, 31, and 37.5% in Group B, respectively.
- Subjects :
- Adult
Antineoplastic Combined Chemotherapy Protocols adverse effects
Aspergillosis chemically induced
Bleomycin administration & dosage
Bleomycin adverse effects
Cyclophosphamide administration & dosage
Cyclophosphamide adverse effects
Doxorubicin administration & dosage
Doxorubicin adverse effects
Drug Resistance, Neoplasm
Etoposide administration & dosage
Etoposide adverse effects
Female
Hodgkin Disease surgery
Humans
Male
Middle Aged
Pericarditis chemically induced
Peripheral Blood Stem Cell Transplantation
Pneumonia chemically induced
Prednisone administration & dosage
Prednisone adverse effects
Procarbazine administration & dosage
Procarbazine adverse effects
Recurrence
Retrospective Studies
Shock, Septic chemically induced
Survival Analysis
Treatment Outcome
Vincristine administration & dosage
Vincristine adverse effects
Young Adult
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Hodgkin Disease drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1029-2403
- Volume :
- 50
- Issue :
- 11
- Database :
- MEDLINE
- Journal :
- Leukemia & lymphoma
- Publication Type :
- Academic Journal
- Accession number :
- 19860621
- Full Text :
- https://doi.org/10.3109/10428190903254383